Track topics on Twitter Track topics that are important to you
KalVista Pharmaceuticals (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, provided an operational update and released financial results for the fiscal first quarter ended July 31, 2018. As quoted in the press release: “Our two recent financings provide significant additional capital for late stage development … Continued
The post KalVista Pharmaceuticals Reports Fiscal First Quarter Results appeared first on Investing News Network.
Original Article: KalVista Pharmaceuticals Reports Fiscal First Quarter ResultsNEXT ARTICLE
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...